CD141, clone: LS17-9, eBioscience™

Description: The monoclonal antibody LS17-9 recognizes mouse CD141 (Thrombomodulin, BDCA-3), a type I cell surface glycoprotein that binds to and allosterically activates thrombin. This complex cleaves protein C and the Thrombin Activatable Fibrinolysis Inhibitor (TAFI), initiating an important anticoagulant and antifibrinolytic pathway. Although expressed across many tissues and cell types, its highest expression has been reported on the lumenal surface of vascular endothelial cell. In the immune system the highest expression can be observed on monocytes and macrophages. Soluble CD141 is constitutively present in the serum at a very low level, and can be upregulated during inflammation. The anti-inflammatory activity of CD141 results from its ability to block the highly pro-inflammatory activity of thrombin. CD141 prevents chemotaxis and binding of granulocytes to activated endothelium, and inhibits activation of eosinophils and mast cells thereby reducing inflammation. Although human CD141 is commonly used as a marker of cross-presenting dendritic cells, mouse CD141 does not exhibit the same expression pattern.Applications Reported: This LS17-9 antibody has been reported for use in immunohistochemical staining of frozen tissue sections, and immunocytochemistry.Applications Tested: This LS17-9 antibody has been tested by immunohistochemistry of frozen mouse tissue and can be used at less than or equal to 10 μg/mL. This LS17-9 antibody has been tested by immunocytochemistry of methanol or formaldehyde-fixed and permeabilized mouse cells and can be used at less than or equal to 10 μg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.Purity: Greater than 90%, as determined by SDS-PAGE.Aggregation: Less than 10%, as determined by HPLC.Filtration: 0.2μm post-manufacturing filtered.